NDA 022548 · Abbvie
Zymaxid
Gatifloxacin · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Sep 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
May 18, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
7 Phase 3, 1 recruiting
FAERS reports
1,785
1,437 serious, 106 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 8, 2016.
ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . ZYMAXID ® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoniae ( 1 )
Mechanism: Gatifloxacin is a quinolone antimicrobial [ see Microbiology ( 12.4 ) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 18, 2010 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewPediatric Medical Review
1 products under this application
- ZYMAXID · GATIFLOXACIN 0.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Gatifloxacin" as an intervention, any sponsor and status, largest first.
- A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary TuberculosisPivotal-lookingStatus unknown
Institut de Recherche pour le DeveloppementGovernment (non-federal)
NCT00216385 · 2,070 participants · Start Jan 2005
Drug: Gatifloxacin combined regimen · For: Tuberculosis
Sites: Cotonou, Benin; Conakry, Guinea; Nairobi, Kenya · 5 sites in all
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00518089 · 859 participants · Start Feb 2008 · Primary completion Jan 2009
Drug: Gatifloxacin 0.5% eye drops; placebo eye drops · For: Bacterial Conjunctivitis
Sites: Downey, California; RajajiNagar, India
- A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00509873 · 578 participants · Start Aug 2007 · Primary completion Jun 2008
Drug: Gatifloxacin 0.5% eye drops; placebo eye drops · For: Bacterial Conjunctivitis
Sites: Gretna, Louisiana
- Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric FeverPivotal-lookingCompleted
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT01421693 · 300 participants · Start Sep 2011 · Primary completion Jul 2014
Drug: Ceftriaxone; Gatifloxacin · For: Enteric Fever; Typhoid Fever
Sites: Kathmandu, Nepal · 2 sites in all
- The Individualized M(X) Drug-resistant TB Treatment Strategy StudyPivotal-lookingTerminated
Centre for the AIDS Programme of Research in South AfricaResearch network
NCT03237182 · 205 participants · Start Jun 14, 2017 · Primary completion Dec 19, 2022
Drug: Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs · For: Tuberculosis, Multidrug-Resistant
Sites: Durban, South Africa
- A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial ConjunctivitisPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00464438 · 171 participants · Start Jun 2007 · Primary completion Sep 2008
Drug: gatifloxacin; moxifloxacin 0.5% eye drops · For: Bacterial Conjunctivitis
Sites: Sacramento, California; Whitby, Canada
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)Pivotal-lookingCompleted
Laboratorios Sophia S.A de C.V.Industry
NCT02980523 · 150 participants · Start Mar 2015 · Primary completion Jun 2016
Drug: PRO-157; Vigamox and 2 more · For: Bacterial Conjunctivitis
Sites: Guadalajara, Mexico
- Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal UlcersPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651586 · 129 participants · Start Oct 2003 · Primary completion Apr 2005
Drug: Gatifloxacin 0.3% ophthalmic solution; Ciprofloxacin 0.3% ophthalmic solution · For: Acute Bacterial Corneal Ulcers; Bacterial Keratitis
Sites: Galveston, Texas; Madurai, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypoglycaemia151
- hyperglycaemia96
- anaphylactic reaction85
- drug intolerance83
- drug ineffective79
- diarrhoea71
- eye pain68
- dizziness58
- off label use56
- dyspnoea55
- rash55
- nausea50
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 299 |
| 2005 | 309 |
| 2006 | 119 |
| 2007 | 42 |
| 2008 | 47 |
| 2009 | 37 |
| 2010 | 40 |
| 2011 | 55 |
| 2012 | 69 |
| 2013 | 41 |
| 2014 | 48 |
| 2015 | 49 |
| 2016 | 56 |
| 2017 | 62 |
| 2018 | 77 |
| 2019 | 100 |
| 2020 | 62 |
| 2021 | 51 |
| 2022 | 53 |
| 2023 | 40 |
| 2024 | 39 |
| 2025 | 41 |
| 2026 | 49 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.
Kuehn R, Stoesser N, Eyre D, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Topical antibiotics for treating bacterial keratitis: a network meta-analysis.
Song A, Yang Y, Henein C, et al. · Cochrane Database Syst Rev 2025 · Network Meta-Analysis, Systematic Review
- Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Ziganshina LE, Titarenko AF, Davies GR · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative Effectiveness of Antibiotic Prophylaxis in Cataract Surgery.
Herrinton LJ, Shorstein NH, Paschal JF, et al. · Ophthalmology 2016 · Comparative Study, Controlled Clinical Trial
- Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery.
Gower EW, Lindsley K, Tulenko SE, et al. · Cochrane Database Syst Rev 2017 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- A novel ciprofloxacin-resistant subclade of H58 Salmonella Typhi is associated with fluoroquinolone treatment failure.
Pham Thanh D, Karkey A, Dongol S, et al. · Elife 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.